Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial (SoraDox)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2014 by Martin-Luther-Universität Halle-Wittenberg.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
PD Dr. med. Matthias Dollinger, Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier:
NCT01272557
First received: January 6, 2011
Last updated: March 31, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)